Aims+Scope/Editorial Board/ Publication information
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Source Type: research
Contents
(Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Source Type: research
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial
Patient-reported outcome (PRO) metrics, including health-related quality of life (HRQoL), are becoming an increasingly important element of clinical trials, including radiotherapy trials. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Authors: Saskia A. Cooke, Jos é S.A. Belderbos, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M.T. Dieleman, Judi N.A. van Diessen, Jan-Jakob Sonke, Dirk de Ruysscher Tags: Original Article Source Type: research
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas
We thank Elmali et al. [1] for the points they raised regarding our paper. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 21, 2024 Category: Radiology Authors: Kelvin Ken Yu, Adam Yeo, Samuel Ngan, Julie Chu, David Chang, Shankar Siva, Aaron Wong, Tomas Kron, Nick Hardcastle, Mathieu Gaudreault, Therese Chesson, Siena Williams, Mark Burns, Sarat Chander Tags: Letter to the Editor Source Type: research
Towards a European prospective data registry for particle therapy
The evidence for the value of particle therapy (PT) is still sparse. While randomized trials remain a cornerstone for robust comparisons with photon-based radiotherapy, data registries collecting real-world data can play a crucial role in building evidence for new developments. This Perspective describes how the European Particle Therapy Network (EPTN) is actively working on establishing a prospective data registry encompassing all patients undergoing PT in European centers. Several obstacles and hurdles are discussed, for instance harmonization of nomenclature and structure of technical and dosimetric data and data protec...
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Cai Grau, Alexandru Dasu, Esther G.C. Troost, Karin Haustermans, Damien C. Weber, Johannes A. Langendijk, Vincent Gregoire, Ester Orlandi, Juliette Thariat, Neige Journy, Abdulhamid Chaikh, Aurelie Isambert, Barbara Alicja Jereczek-Fossa, Ana Vaniqui, Pav Tags: Perspective Source Type: research
Durvalumab impacts progression-free survival while high-dose radiation > 66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR)
Lung cancer is still the most prominent cause for cancer-related deaths worldwide [1]. The majority of patients are diagnosed with non-small cell lung cancer (NSCLC), 30 % of which present in locally advanced stage III [2]. Since the landmark publication by Antonia et al. the standard of care (SoC) for unresectable NSCLC stage III is concomitant chemoradiotherapy (cCRT) 60 – 66 Gy in 2 Gy fractions followed by Durvalumab for one year [3–6]. Although cCRT is preferably recommended by multiple prospective trials [7–11] and one meta-analysis [12], sequential regimens are still frequently used, especially in elder...
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Franz Zehentmayr, Petra Feurstein, Elvis Ruznic, Brigitte Langer, Brane Grambozov, Marisa Klebermass, Herbert H üpfel, Johann Feichtinger, Danijela Minasch, Martin Heilmann, Barbara Breitfelder, Claudia Steffal, Gisela Gastinger-Grass, Karoline Kirchhamm Tags: Original Article Source Type: research
Partially Ablative Body Radiotherapy (PABR): A novel approach for palliative radiotherapy of locally advanced bulky unresectable sarcomas. In regard to Yu et al
We were intrigued by the study conducted by Yu et al. [1] on demonstrating the effectiveness and safety of 'Partially Ablative Body Radiotherapy' (PABR) for treating bulky, unresectable sarcomas. The study introduces a new method called PABR and discusses its outcomes when used on a group of patients with locally advanced, bulky, unresectable sarcomas, including those with a prior history of radiotherapy (RT). We appreciate the authors' innovative work but would like to address some points. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Aysenur Elmali, Erkan Topkan, Cem Onal Tags: Letter to the Editor Source Type: research
Minimum and optimal requirements for a safe clinical implementation of ultra-high dose rate radiotherapy: A focus on patient ’s safety and radiation protection
Studies in multiple animal species have shown that ultra-high dose rate (UHDR) irradiations improve normal tissue sparing while providing equivalent tumor control compared to conventional dose rates. This effect is called the ‘FLASH’ effect (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Cristina Garibaldi, Sam Beddar, Nicola Bizzocchi, Till Tobias B öhlen, Charoula Iliaskou, Raphaël Moeckli, Serena Psoroulas, Anna Subiel, Paige A Taylor, Frank Van den Heuvel, Verdi Vanreusel, Dirk Verellen Tags: Perspective Source Type: research
Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer
Stereotactic Ablative Radiotherapy (SABR) is now an established treatment option for oligometastatic disease. The results of 9 randomised trials support the suggestion that patients with oligometastatic disease treated with ablative therapies such as surgery, SABR or radiofrequency ablation benefit in terms of progression free survival. The treatment is well tolerated [1 –8]. The landmark phase II SABR-COMET trial has shown a doubling of overall survival at 5 and 8 years [9]. With the increase in available data on the benefit of SABR in oligometastatic disease, clinical practice is now starting to incorporate SABR for ...
Source: Radiotherapy and Oncology - April 20, 2024 Category: Radiology Authors: Emma Doyle, Angus J. Killean, Stephen Harrow, Iain D. Phillips Tags: Review Article Source Type: research
Comments on “Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study”
We read the article entitled “Radiotherapy alone versus concurrent chemoradiotherapy in patients with stage II and T3N0 nasopharyngeal carcinoma with adverse features: A propensity score-matched cohort study” by Zhang et al [1] with great interest. The findings of the study indicated that adding concurrent chemotherapy to r adiotherapy did not contribute to improved survival rates in patients with stage II and T3N0 nasopharyngeal carcinoma (NPC) with adverse factors. This is a substantial study as it comprehensively evaluates this controversial issue with a large number of patients and propensity score-matching analysi...
Source: Radiotherapy and Oncology - April 19, 2024 Category: Radiology Authors: Caglayan Selenge Beduk Esen, Gizem Nur Can, Berna Akkus Yildirim Tags: Letter to the Editor Source Type: research
Radiation-associated changes in saliva composition of head and neck cancer patients: A systematic review
Head and neck squamous cell cancer accounts for approximately 4.5% of the newly diagnosed malignancies worldwide, with over 878,000 new cases in 2020 (including lip cancer) [1]. The incidence is rising, especially due to HPV associated head and neck cancer and is expected to increase by 30% until 2030 [2]. Compared to non-HPV related head and neck cancer, often induced by heavy alcohol consumption and/or smoking, the HPV-positive patients usually have a good prognosis after therapy, even with advanced stages of disease at diagnosis. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 19, 2024 Category: Radiology Authors: Michal Staruch, Marlene M. Speth, Peter Neyer, Oliver Riesterer, Daniel M. Aebersold, Sonja Stieb Tags: Review Article Source Type: research
Balancing robustness and adaptation rate for proton therapy of lung cancer patients
Proton therapy aims at accurately delivering high radiation doses to tumors while reducing exposure to surrounding healthy tissue when compared to classical photon-based radiotherapy. The steep dose fall-off at the distal edge of the protons ’ range (the so-called “Bragg Peak”) results in a sharply localized dose peak [1]. This improved conformity when compared to photons comes at the expense of an increased susceptibility to treatment errors such as patient positioning or setup errors, range errors (resulting from the conversion of the CT numbers to proton stopping power ratios (SPRs), and inter- and intra- fraction...
Source: Radiotherapy and Oncology - April 19, 2024 Category: Radiology Authors: Vlad Badiu, Vicki Trier Taasti, Gilles Defraene, Wouter van Elmpt, Edmond Sterpin Tags: Original Article Source Type: research
Could a low-dose definitive radiation therapy be the optimal treatment for choroidal hemangioma?
Choroidal hemangioma is a benign vascular tumor presenting in circumscribed and diffused forms, often leading to profound visual loss. In symptomatic cases, 50% of patients present with a visual acuity of 20/200 or worse in the long term if untreated [1]. The management of circumscribed choroidal hemangioma (CCH) has evolved over the past several decades from laser photocoagulation, transpupillary thermotherapy, and radiotherapy to the wide usage of recent photodynamic therapy (PDT). (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Li Wang, Tianci Tang, Jie Wang, Tong Lin, Yi Li, Xinmao Song Tags: Original Article Source Type: research
Assessing radiation-induced carotid artery injury using ultrasound in patients with head and neck cancer
Head and neck cancers (HNC) are among the most prevalent malignant tumors worldwide. They encompass malignancies of the upper respiratory tract and gastrointestinal system, including nasopharyngeal carcinoma, laryngeal carcinoma, tongue carcinoma, parotid gland carcinoma, and others [1]. The development of HNC is closely related to smoking, excessive drinking, chewing of betel nuts, and viral infection (HBV/HPV). The treatment of HNC includes surgery, radiotherapy (RT), chemotherapy, and immunotherapy. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Zhuangzhuang Zheng, Yingying Shen, Jing Su, Xiaorui Ji, Qiang Zhang, Qin Zhao, Xin Jiang Tags: Original Article Source Type: research
Predictive factors for radiation-induced pituitary damage in pediatric patients with brain tumors
Multiple studies have demonstrated hypothalamic –pituitary dysfunction in survivors of childhood and adolescent brain tumors. Hypothalamic-pituitary dysfunction may reflect direct injury by the tumor itself or by surgery, as well as treatment-induced damage, mainly due to cranial irradiation. Other risk factors for pituitary hormone deficiencie s include concurrent chemotherapy and young age at the time of irradiation [1–7]. Hypothalamic-pituitary dysfunction secondary to radiation is time-dependent, with both increased incidence and severity of hormonal deficits with longer follow-up [8]. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - April 17, 2024 Category: Radiology Authors: Larisa Gorenstein, Shai Shrot, Michal Ben-Ami, Eve Stern, Michal Yalon, Chen Hoffmann, Shani Caspi, Michal Lurye, Amos Toren, Gadi Abebe-Campino, Dalit Modan-Moses Tags: Original Article Source Type: research
